9/8/2010

Roche Holding is collaborating with Belgium's reMYND to develop two of the latter's preclinical compounds, which suppress tau neurotoxicity in Alzheimer's disease and alpha-synuclein neurotoxicity in Parkinson's disease. ReMYND might receive from Roche more than $637 million in milestone fees, plus royalties.

Full Story:
Reuters

Related Summaries